Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Departments

In reply: Metformin for type 2 diabetes January 2019

Vinni Makin, MBBS, MD, FACE and M. Cecilia Lansang, MD, MPH
Cleveland Clinic Journal of Medicine April 2019, 86 (4) 237; DOI: https://doi.org/10.3949/ccjm.86c.04004
Vinni Makin
Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Cecilia Lansang
Cleveland Clinic
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

We thank Dr. Moskowitz for his kind comments. We agree about the need for assessing vitamin B12 levels during chronic metformin use.

Secondary analysis of patients in the Diabetes Prevention Program Outcomes Study showed a higher incidence of combined low and low-normal vitamin B12 deficiency in users assigned to the metformin group compared with those assigned to the placebo group at the 5-year and 13-year marks after randomization.1 Post hoc analysis of patients in the Hyperinsulinemia: the Outcome of Its Metabolic Effects trial also showed lower levels of vitamin B12 and higher levels of methylmalonic acid associated with significant worsening of a validated neuropathy score in metformin users.2

The mechanism behind the development of vitamin B12 deficiency is not completely understood but could possibly be alterations in intestinal mobility, bacterial overgrowth, or calcium-dependent uptake by ileal cells of the vitamin B12-intrinsic factor complex.3

Our electronic medical record has a built-in tool that suggests checking vitamin B12 whenever a patient requests metformin refills. There are no current guidelines on the need for baseline testing of the vitamin B12 level. The American Diabetes Association recommends periodic measurement of vitamin B12 levels, possibly yearly, in metformin users and more often if there are symptoms indicative of deficiency.4

  • Copyright © 2019 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Aroda VR,
    2. Edelstein SL,
    3. Goldberg RB,
    4. et al
    5. Diabetes Prevention Program Research Group
    . Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2019; 101(4):1754–1761. doi:10.1210/jc.2015-3754
    OpenUrlCrossRef
  2. ↵
    1. Out M,
    2. Kooy A,
    3. Lehert P,
    4. Schalkwijk CA,
    5. Stehouwer CDA
    . Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: post hoc analysis of a randomized controlled 4.3 year trial. J Diabetes Complications 2018; 32(2):171–178. doi:10.1016/j.jdiacomp.2017.11.001
    OpenUrlCrossRef
  3. ↵
    1. Liu KW,
    2. Dai LK,
    3. Jean W
    . Metformin-related vitamin B12 deficiency. Age Ageing 2006; 35(2):200–201. doi:10.1093/ageing/afj042
    OpenUrlCrossRefPubMed
  4. ↵
    1. American Diabetes Association
    . 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2019. Diabetes Care 2019; 42(suppl 1):S90–S102. doi:10.2337/dc19-S009
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 86 (4)
Cleveland Clinic Journal of Medicine
Vol. 86, Issue 4
1 Apr 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In reply: Metformin for type 2 diabetes January 2019
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
Please verify that you are a real person.
Citation Tools
In reply: Metformin for type 2 diabetes January 2019
Vinni Makin, M. Cecilia Lansang
Cleveland Clinic Journal of Medicine Apr 2019, 86 (4) 237; DOI: 10.3949/ccjm.86c.04004

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In reply: Metformin for type 2 diabetes January 2019
Vinni Makin, M. Cecilia Lansang
Cleveland Clinic Journal of Medicine Apr 2019, 86 (4) 237; DOI: 10.3949/ccjm.86c.04004
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Departments

  • When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
  • Our Peer-Reviewers for 2023
  • Our Peer-Reviewers For 2022
Show more Departments

Letters to the Editor

  • In Reply: In defense of the anion gap
  • In defense of the anion gap
  • In Reply: Insomnia in older adults
Show more Letters to the Editor

Similar Articles

Subjects

  • Diabetes
  • Endocrinology
  • Geriatrics

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire